

9th **AMR CONFERENCE**

Novel Antimicrobials & AMR Diagnostics




25 – 26 February 2025

Congress Center Basel | Switzerland






Program at a glance

Conference Day 1 | 25 February 2025

07:00 – 19:30	Registration open		
08:45 – 10:30	BEAM Alliance General Assembly (BEAM members only)		Room Osaka
09:00 – 10:30	Workshop “Translational challenges in clinical development”		
	      	Room Sydney	
10:00 – 19:00	1-to-1 partnering meetings exhibition open		
11:00 – 12:00	Opening Plenary		
	Taking action after renewed political commitment		Room Sydney
12:00 – 13:30	Lunch break		
13:30 – 14:30	Plenary Session		
	Translating AMR clinical needs from local to global		Room Sydney
15:00 – 16:00	Parallel Sessions		
	Remarkable advances in AMR science  Room Sydney	Technology corner in diagnostics  Room Singapore	Pathogen reduction approaches to prevent AMR Room Osaka
16:00 – 16:30	Poster presentations		
16:30 – 17:30	Parallel Sessions		
	PK/PD modelling to improve the translation of doses to clinic Room Sydney	A sustainable investment ecosystem in Europe for AMR Room Singapore	Developing biologics for global purposes Room Osaka
18:00 – 19:30	Start-up pitch  		Room Sydney
19:30 – 21:30	Reception in the exhibition hall		

Program at a glance

Conference Day 2 | 26 February 2025


08:00 – 18:30	Registration open		
08:30 – 18:00	1-to-1 partnering meetings exhibition open		
08:30 – 09:30	Plenary Session		
	Past failure, future successes		Room Sydney
10:00 – 11:00	Parallel Sessions		
	Clinical trials: combining drugs, not problems	Challenges in diagnostic uptakes	The growing threat of sexually transmitted infections
	Room Sydney	Room Singapore	Room Osaka
11:00 – 11:30	Poster presentations		
11:30 – 12:30	Plenary Session		
	Manufacturing is not only a post-marketing topic		Room Sydney
12:30 – 14:00	Lunch break		
14:00 – 15:00	Parallel Sessions		
	Clinical endpoints: fit-for-purpose?	Towards an EU multi-country PULL mechanism	One Health, climate and innovation
	 tranScrip		 GLOBAL AMR R&D HUB
	Room Sydney	Room Singapore	Room Osaka
15:30 – 16:30	Parallel Sessions		
	Making the most of external expertise	Innovation for access to effective antibiotics	Technology update
		Room Singapore	
	Room Sydney		Room Osaka
16:45 – 17:00	Awarding of poster prizes		
			Room Sydney
17:00 – 18:00	Closing Plenary		
	Communicating on AMR, a simple matter of wording?		Room Sydney
18:00 – 19:00	Farewell reception in the exhibition hall		

Floor plan



- Exhibition booths
- Private meeting rooms
- Conference rooms
- Catering
- Media table

Venue:
Congress Center Basel
2nd floor
Messeplatz 21
4058 Basel, Switzerland



SSID: Free-Messe-Basel
Free SMS Login
(one login for each device)

Exhibitors

Booth	Exhibitor
# 1	Pathways to Antimicrobial Clinical Efficacy (PACE)
# 4	Immunochem
# 5	ERBC Group
# 6	Biovitae
# 7	Vibiosphen
# 9	INCATE
# 10	German Center for Infection Research e.V. / Global AMR R&D Hub
# 11	Micron Research Ltd
# 12	IMI AMR Accelerator
# 13	Firefinch Software Ltd
# 14	European Clinical Research Alliance on Infectious Diseases (ECRAID)
# 15	P3NET
# 16	WuXi AppTec Ltd
# 17	BioVersys AG
# 18	Selvita S.A.
# 19	Aurobac Therapeutics SAS
# 20	Rime Bioinformatics SAS
# 21	Global Antibiotic Research & Development Partnership
# 22	Basilea Pharmaceutica International Ltd
# 23	PrecisionPhage Ltd
# 24	Infex Therapeutics Ltd
# 25	Leibniz Health Technologies
# 26	Infectogenics Research Campus Jena e.V.
# 27	Hapila GmbH
# 28	Collaborative Drug Discovery Ltd
# 29	Tianshi Capital
Room Guangzhou	F. Hoffmann-La Roche Ltd
Room Hong Kong	WuXi AppTec Ltd
Room Mexico	Innovate UK

Poster presentation

No.	Title	Corresponding Author
1	Patient-specific point-of-care system for rapid combination therapy of fungal infections- Mykopoint	Sophie Becke, Charité Universitätsmedizin Berlin
2	Ultra-Fast Pathogen Identification in Sepsis Diagnosis Using an Optomechanical Sensor Assisted by Artificial Intelligence	Blanca Caballero, Nanological
3	Interim Results from the Analytical Validation of Rapid Direct from Urine and Urine Isolate Microcapillary Antimicrobial Susceptibility Testing (AST)	Julie Hart, Astratus Ltd.
4	Same day visual bacterial identification and semi-quantitative antibiotic sensitivity assay directly from clinical samples	Roshan Naik, Diagopreutic Pvt. Ltd.
5	CRISPR-based diagnostics for resistance guided therapy of gonorrhea at the point-of-care	Carolina Paganini, ETH Zurich
6	Rapid and specific detection of pathogenic bacteria using recombinant receptor binding proteins of bacteriophages	Leonie Reetz, Fraunhofer Institute for Translational Medicine and Pharmacology
7	MyLabReady® for rapid and accurate point of care (POC) diagnosis of symptomatic infections and AMR guidance	Leonard Weisman, LabReady Ltd
8	Accelerating single-domain antibody discovery against S.aureus ClfA to combat Antimicrobial Resistance (AMR): A high-efficiency yeast surface display platform	Geoffrey Holsbeek, Immunochem
9	Pan-Candida monoclonal antibodies as novel immunotherapies to treat drug resistant life-threatening invasive candidiasis	Carol Munro, University of Aberdeen
10	Designing metabolically enhanced next-generation probiotics to eradicate multi-drug resistant bacteria from the gut	Lisa Osbelt, Helmholtz Centre for Infection Research
11	Exploring the Association Between Study Characteristics and Post-Vaccine Immunogenicity for C. diff: Data-Driven Analyses of Two Vaccine Trials	Igor Stojkov, Paul-Ehrlich-Institute
12	Exploring antimicrobial activities of extremophilic bacteriophages	Abeer M. Abduljawad, University of Jeddah
13	Exploring Antimicrobial Activities of Isolated Bacteriophages from Water Contaminated by House Fly (Musca domestica)	Afrah Ammar Altalhi, University of Jeddah
14	Understanding Bacterial Resistance Mechanisms: Insights from Porin Mutations in Klebsiella pneumoniae	Matteo Ceccarelli, University of Cagliari
15	Fibrilysins as next-generation endolysins targeting multicellular staphylococcal communities	Vincent De Maesschalck, KU Leuven

Poster presentation

No.	Title	Corresponding Author
16	HY-133, a chimeric endolysin in the clinical development for nasal decolonization of <i>Staphylococcus aureus</i>	Evgeny Idelevich, University Hospital Greifswald
17	<i>Pseudomonas aeruginosa</i> secondary metabolite activates lysis–lysogeny switch leads to prophage induction in <i>Staphylococcus aureus</i>	Shubham Joge, University of Vienna
19	LysGN as a potential enzybiotics against Gram-Negative ESKAPE Pathogens	Ruqaiyah Khan, Indian Institute of Technology
20	Bacteriophage, or ‘phage’ products represent a powerful strategy to combat the escalating global burden of bacterial antimicrobial resistance (AMR)	Matthew Lamaudière, Medicines and Healthcare Products Regulatory Agency
21	AI-Driven Prediction of Phage Receptor-Binding Proteins for Phage Therapy	Hanshuo Lu, University of Liverpool
22	LYSG101: A Highly Potent Chimeric Bacteriophage Lysin Against <i>Staphylococcus aureus</i>	Assaf Raz, Precision Biotix Therapeutics
23	Discovery of Immune-Responsive Gene 1 (IRG1) Modulators as Potential Host-Directed Anti-infective Agents	Gabriele Bianchi, Helmholtz Institute for Phar- maceutical Research Saarland
24	Discovery & Exploratory Research at the Global Antibiotic Research & Development Partnership (GARDP): Objectives and Progress	Benjamin Blasco, GARDP
25	Combining growth inhibition assays and metabolic profiling to accelerate discovery of antibiotics with unconventional modes of action	Benjamin Demarco, University of Basel
26	A novel class of metalloid-based antibiotic compounds	Angelo Frei, University of York
27	Trichloroacetimidamides: a novel class of specific antibiotics	Juan Garcia-Sanchez, Université Côte d’Azur
28	Split inteins for generating combinatorial nonribosomal peptide libraries	Patrick Gonschorek, Max Planck Institute for Terrest- rial Microbiology
29	Disperazol platform-technology: the solution to the developing AMR crisis?	Michael Graz, Disperazol Pharma ApS
30	Identification, Optimization and Validation of a New Triaromatic Pleuromutilin Antibiotic Subclass	Christoffer Heidtmann, University of Southern Den- mark
31	Mucus-derived glycans as a therapeutic strategy for cross-kingdom pathogens	Rachel Hevey, University of Basel

Poster presentation

No.	Title	Corresponding Author
32	Dipeptidic Phosphonates: Potent Inhibitors of Pseudo-monas aeruginosa Elastase B Showing Efficacy in an in vivo Murine Keratitis Model and an ex vivo Human Cornea Assay	Lukas Hiller, HIPS
33	CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis	Lesley Jenkinson, MD Catapult
34	In Vivo Activity Profiling of Biosynthetic Darobactin D22 Against Critical Gram-negative Pathogens	Andreas Kany, HIPS
35	An innovative antibacterial drug discovery system and its results: lysocin E	Takeo Kohda, Silk Strand Pharmaceuticals Co., Ltd.
36	Targeting the Bacterial Sliding Clamp for the Treatment of Gram-Positive Bacterial Infections	Niklas Krappel, HIPS
37	Targeting the dynamic BAM-SurA holo insertase complex with novel antibiotics	Philippe Lehner, University of Basel
39	Design, synthesis, in vitro and in vivo evaluation of unexplored trisindolines as potent anti-MRSA agents targeting cell membrane	Avishek Mahapa, CSIR-Indian Institute of Integrative Medicine
40	Biotechnological methodologies for BamA Inhibitor derivatization	Michael Marner, Justus-Liebig-University of Giessen
42	Preclinical development of vancomycin polycationic peptide conjugate (VN-R6C) with high antimicrobial activity in vitro and in vivo	Eric Mühlberg, University of Heidelberg
43	CRS3123: A Narrow Spectrum Agent for Treatment of C. difficile Infection (CDI)	Urs Ochsner, Crestone, Inc.
44	Broadening of the antifungal pipeline by the use of polymeric nanoparticles	Thomas Orasch, Leibniz HKI
45	Discovery of novel oxepanoprolinamide antibiotics effective against multidrug-resistant bacteria	Lloyd Payne, Kinvard Bio, Inc.
46	Development of the natural product Corallopyronin A to treat filarial nematode infections and antibiotic-resistant staphylococci infections	Kenneth Pfarr, University Hospital Bonn
47	Addressing AMR in Helicobacter pylori by FDA-approved drugs as novel anti-infectives	Dietmar Pfeiffer, Technical University of Munich
48	Some antiretroviral therapies inhibit the growth of selected cervicovaginal microbes with potential protective role in pre-term birth	Veronica Preda, Imperial College London
49	The missing piece in the puzzle: APC148 – a safe, selective and efficient metallo- β -lactamase inhibitor	Pål Rongved, Adjutec Pharma AS

Poster presentation

No.	Title	Corresponding Author
50	Innovative Aminoglycosides: Potent, Safe, and Orally Bioavailable Antibiotics Against AMR	Kaloud Salama, Palacky University Olomouc
51	MraY Enzyme: Crucial Target for Innovative Antibiotics	Kaloud Salama, Palacky University Olomouc
52	Battlestar™: A Biodegradable Delivery System for Addressing AMR and Biofilm-Associated Infections Using in situ Generated Oxidative Biocides	Harsha Siani, AGA Nanotech Ltd.
53	Identification of mucosal glycans that regulate the acute-to-chronic infection switch in <i>Pseudomonas aeruginosa</i>	Alem Storani, University of Basel
54	Semisynthetic Amides of Polyene Antibiotic Natamycin	Anna Tevyashova, Constructor University
55	Small molecule antibiotic against <i>A. baumannii</i> without cross-resistance and potential new MoA	Alexander Titz, Helmholtz Centre for Infection Research
56	Peptide-modified β -lactam antibiotics with an extended efficacy spectrum	Philipp Uhl, Heidelberg University Hospital
57	Potent in vivo efficacy demonstrated for epidermicin NI01 in an MRSA wound infection model	Mathew Upton, Amprologix Ltd
58	Repurposing Bismuth-Based Drugs to Overcome Antibiotic Resistance in <i>Pseudomonas aeruginosa</i>	Auke van Heel, Omnicin Therapeutics BV
60	Inhibiting Bacterial Biofilms to Potentiate Antibiotics and Prevent Recurrent Infections	Ash Zarkan, BioTrypt Therapeutics
61	The antibiotic discovery accelerator (ABX); catalysing anti-microbial discovery from academia through industry into the clinic	Jonathan Cox, Aston University
62	Cystic fibrosis sputum media induces an overall loss of antibiotic susceptibility in <i>Mycobacterium abscessus</i>	Jonathan Cox, Aston University
63	A model to investigate anti-virulence strategies against <i>Salmonella</i>	Alaa Alhayek, University of Basel
64	Poly(N-acryloyl-D-aminoalanine) shows anti-Staphylococcus aureus biofilm activity using both in vitro and in vivo models	Marco Chittò, AO Research Institute Davos
65	RaMoA: Combination of Raman micro-spectroscopy with deep learning for rapidly predicting the Mechanism of Action of an antimicrobial and its potential novelty	Sophie Dixneuf, Bioaster
66	<i>Escherichia coli</i> resistance against 'living antibiotic' <i>Bdellovibrio bacteriovorus</i>	Simona Huwiler, University of Zurich
67	Relating Outer Membrane Permeability with Activity in <i>E. coli</i> by Employing Statistics-Based Machine Learning	Stefan Milenkovic, University of Cagliari

Poster presentation

No.	Title	Corresponding Author
68	The role of an uncharacterized family of α/β -hydrolases in the antimicrobial resistance	Iryna Myziuk, University of Saskatchewan
69	Unraveling the role of the Central metabolism in mediating tolerance in Uropathogenic Escherichia coli	Yannick Revaz, University of Basel
70	Development of a Synthetic Human Urine formulation for the study of UPEC physiology and the discovery of antibiotics	Benjamin Sellner, University of Basel
71	Benefits of group sequential design and sample size re-estimation for RCTs evaluating the prevention of ventilator-associated pneumonia: A simulation study informed by real world data	Holly Jackson, Geneva University Hospital
72	AMRObit Scorecard: A Dynamic Phase Space Model for Strategic Monitoring and Actionable Insights on Global AMR Trajectories in Urinary Tract Infections	Jasmine Kaur, Indraprastha Institute of Information Technology
73	From awareness to ac-on: can we do more to combat antimicrobial resistance in heavily immunocompromised patients?	Diego Lopez, Menarini Global Team
74	Recommended Approaches for Integration of Population Pharmacokinetic Modelling with Precision Antibiotic Dosing in Clinical Practice	Emily Heron, Vesynta Ltd.
75	Preclinical murine models for studying lung infections and antimicrobial treatments of nontuberculous mycobacteria	Nicola Lorè, IRCCS Ospedale San Raffaele
76	An in vivo-like lung infection model for pharmacokinetics and -dynamics studies	Leoni Swart, University of Basel
76b	A PK/PD modelling workflow for evaluating empirical antibiotic combination therapies: application to neonatal sepsis in the BARNARDS study	Wisse van Os, Leiden University
77	DEVELOPMENT OF A MUCIN GLYCAN LIBRARY FOR STUDYING VIRULENCE ATTENUATION IN PATHOGENS	Carmen Cori Calizaya, University of Basel
78	Medical devices with non-antibiotic antimicrobial surface coatings: A preventive approach to combat biofilm formation and bacteria dissemination	Skander Hathroubi, Spartha Medical

Sponsors, exhibitors and partners

PLATINUM



GOLD



SILVER



BRONZE



LOCAL HOST



SUPPORTING PARTNERS





bamconn

10th AMR CONFERENCE

Novel Antimicrobials & AMR Diagnostics

3 – 4 March 2026

Congress Center Basel | Switzerland

Save the date

Venue Congress Center Basel
Messeplatz 21, 4058 Basel, Switzerland

Conference office bamconn GmbH
info@amr-conference.com, +49 176 10 14 39 86



Stay
informed



Follow
us on
LinkedIn